Edwin Elmhirst

Data Journalist at Scrip

Data journalist at Citeline

Featured in: Favicon

evaluate.com Favicon

informa.com (+3) Favicon

citeline.com (+1)

Articles

Oncology’s Most Eligible Unpartnered Assets

1 month ago | insights.citeline.com | Edwin Elmhirst

Oncology’s Most Eligible Unpartnered AssetsEvaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
China’s Biotech Stocks Proved More Resilient Than US Amid Market Turmoil

1 month ago | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst |Dexter Yan

China’s Biotech Stocks Proved More Resilient Than US Amid Market TurmoilStart-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma

2 months ago | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

Unpartnered Obesity Assets Are Becoming Slim Pickings For PharmaEvaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.
After Obesity, What Are Biopharma’s Big Growth Markets?

Feb 27, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

After Obesity, What Are Biopharma’s Big Growth Markets? The five therapy areas forecast to achieve the highest growth between 2024 and 2030 include a mixture of the more obvious (MASH) and less high profile (glioma). In some cases, which companies will seize market share remains up for grabs.
Five Companies Heading Toward 2030 With Wind At Their Back

Feb 26, 2025 | insights.citeline.com | Jessica Merrill |Edwin Elmhirst

Five Companies Heading Toward 2030 With Wind At Their BackWhich Big Companies Face The Least LOE Hit? Novo, Sanofi, Gilead, Lilly and Bayer are among the big pharmas with the fewest expected US exclusivity losses from 2026-2030.
Licensing For Innovation: A Decade Of Pharma Product Deals

Feb 24, 2025 | insights.citeline.com | Edwin Elmhirst

Licensing For Innovation: A Decade Of Pharma Product DealsLicensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
2025’s Biggest New Launches

Feb 19, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

2025’s Biggest New Launches Big pharma once again fails to dominate the top 20 expected best sellers from products due for launch this year. Small-to-medium pharma account for nearly half the list, while Vertex has two products in the top five.
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024

Feb 10, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024Summit Therapeutics hit the stock market heights in 2024, along with a handful of biotech with novel therapies and platforms, while Moderna was dragged down by shrinking COVID-19 vaccine sales.
Only Half Of 2024’s Biggest Launches Belong To Big Pharma

Jan 16, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

Only Half Of 2024’s Biggest Launches Belong To Big Pharma Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.
Scrip | In-Depth Insights Beyond the Headlines | Insights

Jan 7, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst |Jessica Merrill |Andy Smith

In Vivo's latest Outlook magazine is live! Visit the microsite to download the report. Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.